each other, in contrast to the promoter of the gene encoding IFN-λ1, which is evolutionarily more divergent from those of the other two cytokines in the type III interferon family.
Collectively, results from the present study by Odendall et al. 3 have important implications for virus-host interactions and elucidate the mechanism of the differences in the induction of interferon from distinct cellular organelles. They have solved an important piece of the IFN-λ puzzle and have shed light on the broader question of why type III interferons exist and how they may complement the canonical type I interferons. Together with the published finding that signaling by IFN-λ is quantitatively and dynamically distinct from that of IFN-α and IFN-β 16 , there is now greater understanding about this functional dichotomy, which calls for further exploration of the specific role of IFN-λ in the immune system. This important study also provides insight into how cells not of the immune system are able to spatially coordinate the initiation of interferon signaling to achieve an optimal antiviral response.
with biochemical and imaging tools. Finally, the question remains open of whether the induction of IFN-λ in cells of the immune system, such as plasmacytoid dendritic cells, in which Toll-like receptors have a critical role in sensing incoming pathogens, follows a different pattern than that observed for the cells that are not part of the immune system, such as those examined in this study 3 .
On the pathogen side, it is possible to speculate that viruses have evolved strategies to target the RIG-I-MAVS-pex-IRF1-IFN-λ axis to suppress initiation of the type III interferon response. For example, Kaposi's sarcoma-associated herpesvirus encodes ORF K9, a viral mimetic of host IRF1 that inhibits IFN-β expression 11 , which may antagonize the induction of type I interferons and type III interferons differently in certain cell types. Another example is the NS3/4A protease from hepatitis C virus, known to efficiently cleave MAVS localized to mitochondria-associated endoplasmic reticulum membranes and to block events downstream of RIG-I signaling 12 . Whether NS3/4A also cleaves MAVS-pex and thus attenuates the peroxisome-derived IFN-λ response is not known. Interestingly, although the 3′ untranslated region-encoded RNA pathogen-associated molecular pattern of hepatitis C virus can activate the expression of both IFN-α and IFN-λ in plasmacytoid dendritic cells 13 , infection of hepatocytes with hepatitis C virus seems to readily induce IFN-λ expression but not IFN-α expression 14, 15 , which suggests the possibility of virus-and cell type-specific activation of IFN-λ. Finally, it remains unclear whether the same regulatory mechanism that controls IFN-λ1 also applies to IFN-λ2 and IFN-λ3, especially given that the promoter regions of the genes encoding IFN-λ2 and IFN-λ3 are almost identical to knocked down by small interfering RNA with MAVS localized to specific cellular compartments, they demonstrate that MAVS present in mitochondria acts upstream of both type I interferons and type III interferons, whereas signaling via MAVS-pex activates exclusively IFN-λ and is sufficient to suppress the replication of vesicular stomatitis virus. In addition, they find that during the differentiation of polarized intestinal epithelial cells, there is a functional link between peroxisome biogenesis and the ability of these cells to express IFN-λ but not IFN-β in response to viral infection. Furthermore, the chemical disruption of mitochondria shifts cells from a type I interferon-dominant expression paradigm to a solely IFN-λ pattern. Finally, in cells from patients with Zellweger syndrome, which lack functional peroxisomes to various degrees, the authors make the interesting finding that a misformed mitochondria-peroxisome 'hybrid' organelle leads to enhanced signaling via RIG-I-MAVS, although they do not report whether these cells are defective in IFN-λ production.
While the novel discovery of selective induction of IFN-λ from peroxisomes is mechanistically intriguing, several new questions arise from this work. Despite the evidence that IFN-λ fits the profile of the secreted antiviral molecule downstream of MAVS-pex, the possibility cannot be excluded that another undefined cytokine or growth factor may also activate a similar Jak-STAT pathway and thereby confer the protective effect. In addition, it has been reported that the formation of higher order structures resembling those of prions and inflammasomes is necessary for intact MAVS signaling 10 . Whether the oligomerization of MAVS at peroxisomes is required for the induction of type III interferons is unknown and calls for further analysis enhancing the understanding of asthma
The chromatin signature of genomic enhancers in CD4 + T cells distinguishes asthmatic patients from healthy subjects. A llergic diseases, particularly asthma, pose a growing medical challenge worldwide. CD4 + T cells, which are critical for host defense against infection, can also instigate a detrimental inflammatory response to harmless environmental substances such as pollens. This misdirected immune response may then lead to allergic disease. A strong genetic basis has been established for asthma, but despite advances in genomics identifying associated loci, a substantial proportion of the causality remains unexplained. In addition to the effect of genetics, the environment also greatly affects disease, with asthma and allergies serving as profound examples of this influence. In this issue, Seumois et al. establish the feasibility of measuring modifications of DNApackaging proteins in populations of primary human CD4 + T cells and using this information to better understand the foundations of asthma 1 . The authors focus on a marker of genomic enhancers, histone 3 dimethylated at Lys4 (H3K4me2). This study therefore other exposures, including smoking and pollution, as well as hygiene and antibiotic use, seem to be associated with the development and progression of this disease 4 .
The link between genetic and environmental influences on asthma can be captured by epigenetic profiling. Epigenetics refers to the study of the packaging of DNA into a structure called 'chromatin' and the effects of variable chromatin organization on activity of genetic regulatory elements. In addition to a set of inherited epigenetic marks, there are probably nonheritable epigenetic marks that are more dynamic and change in response to environmental stimuli 4, 5 .
During the past few years, advances in the epigenomic annotation of functional noncoding elements, commonly referred to as 'enhancers' , have begun to shed light on gene regulation at the genetic and epigenetic levels. Enhancers are associated with distinct chromatin structures that display unique histone modifications. Various developments in genomic technology, such as chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq), have enabled the construction of genome-wide maps of enhancers through the use of global patterns of such histone modifications. Comparisons of enhancer maps in a variety of cell types have revealed represents an important step in delineating how genetic risk and the effect of the environment on the T cell epigenome come together to affect disease.
More than a decade ago, geneticists envisioned principles for genetic mapping using populations rather than families to study common diseases such as asthma. This approach, coined 'genome-wide association study' , tests a comprehensive catalog of common genetic variants in patients and control subjects in a population to identify variants associated with a particular disease. Although genome-wide association studies have had key roles in discovering a few major genes and pathways that drive immune system-mediated disorders 2 , the outcomes for asthma 3 and many other diseases have been largely sobering: much susceptibility cannot be explained by common genetic variants, and of the disease-associated variants identified, the majority are noncoding, which complicates assessment of their function.
Beyond genetics, environment is also a key participant in the pathogenesis of asthma. Moreover, the considerable increase in the prevalence of asthma over the past few decades, especially in developing countries, suggests that environmental factors also influence disease development. Although allergens are classically associated with asthma, many Debbie Maizels/Nature Publishing Group substantial cell-type specificity. Particularly important for understanding genetic associations with disease was the realization that a DNA variant can disrupt or generate a transcription factor-binding site within an enhancer. This notion suggests that with the enhancer map of a disease-relevant cell type, the functionality of noncoding variants associated with the disease might be assessed.
ChIP-seq experiments begin with immunoprecipitation of genomic fragments, followed by the preparation of a library for high-throughput sequencing to identify isolated genomic regions 6 . Due to inefficiencies at the steps of immunoprecipitation and library preparation, this procedure requires large amounts of starting material, which prevents its application to the study of rare, biologically important cell types.
Several groups have developed small-scale immunoprecipitation protocols to overcome the challenges related to inefficiencies at the ChIP step 6 , but Seumois et al. are the first to tackle this problem in primary populations of cells of the immune system obtained from patients 1 . The chromatin landscapes of helper T cells have been extensively studied for cells generated in vitro from both humans and mice 5, 7, 8 ; however, Seumois et al. present the first enhancer maps of T cells generated in vivo 1 (Fig. 1) . Their work focuses on the T helper type 2 (T H 2) subset of CD4 + T cells, which are key participants in asthma. The authors isolate circulating naive and memory CD4 + T cells from peripheral blood of healthy control subjects and patients with asthma and then further subdivide the CD4 + memory T cells on the basis of their surface expression of the chemokine receptor CCR4 to enrich for T H 2 cells. They use the histone modification H3K4me2 for ChIP-seq as a reliable indicator of enhancer elements, following a number of studies highlighting the utility of H3K4me2 in identifying poised and active enhancer domains across the genome.
The message that emerges from this study is that enhancers in cell populations that have undergone enrichment for T H 2 cells harbor a large portion of asthma-associated genetic variants. Furthermore, comparison of enhancers identified in healthy control subjects versus patients with asthma high lights the finding that the majority of differences in H3K4me2 distribution appear in populations enriched for T H 2 cells rather than in other memory or naive CD4 + T cell populations.
The most intriguing aspect of this study is its proof-of-concept for generating histone modification-based enhancer maps for primary cells of the immune system, particularly for small cell populations in tissues from increasingly routine for doctors to perform whole-exome sequencing. No doubt sooner than expected, it will be reasonable for a patient to ask, "Hey doc, should you check my epigenome?" Due to compositional heterogeneity of tissue samples from patients, methods that use sorted cell populations will probably prove more effective for epigenomic approaches. The development of an assay for transposase-accessible chromatin using sequencing (ATAC-seq) 13 , which allows the profiling of 'open' chromatin from blood populations in a timeline on the order of days, has brought progress toward this goal. Now a technology for epigenome mapping in small cell populations from clinical samples can be added to the list. As these technologies emerge, it becomes increasingly important to understand how all of these '-omic' measurements relate to each other and to downstream physiological consequences if such technology is to be used one day to determine a means of intervention.
